Favorable Equivalency Studies of Candidate Biosimilar AVT04 and Reference Ustekinumab
Posters presented by Alvotech at 2023 American Academy of Dermatology (AAD) annual meeting showcased proven bioequivalence and therapeutic equivalence candidate biosimilar AVT04 and reference ustekinumab (Stelara).
Samsung Bioepis’ Stelara Biosimilar Proves Successful in Phase 1 Study
At the American Academy of Dermatology annual meeting, Samsung Bioepis shared positive results from a phase 1 study comparing its ustekinumab biosimilars (SB17) with the reference product (Stelara).
Cyltezo Is a Contender for First Interchangeable to Humira, Boehringer Ingelheim Says
The results of Voltaire-X could persuade the FDA to authorize automatic substitution of the adalimumab biosimilar Cyltezo for its reference product (Humira), investigators believe.
2 Clarke Drive Cranbury, NJ 08512